ECSS
RXRX icon

Eurizon Capital SGR SpA’s Recursion Pharmaceuticals RXRX Stock Holding History

Eurizon Capital SGR SpA’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$470K Buy
128,059
+32,259
+34% +$107K ﹤0.01% 657
2026
Q1 		$294K Buy
95,800
+606
+0.6% +$2.34K ﹤0.01% 699
2025
Q4 		$389K Buy
+95,194
New +$471K ﹤0.01% 598

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Eurizon Capital SGR SpA's RXRX Position: Q2 2026 in Review

Eurizon Capital SGR SpA increased its Recursion Pharmaceuticals (RXRX) stake by 34% in Q2 2026, buying an estimated $107K and bringing the position to 128,059 shares worth $470K. The position accounts for ﹤0.01% of the portfolio, ranked #657.

Eurizon Capital SGR SpA first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Eurizon Capital SGR SpA held 128,059 shares of Recursion Pharmaceuticals worth $470K as of Q2 2026.
  • Eurizon Capital SGR SpA bought 32,259 Recursion Pharmaceuticals shares in Q2 2026, an estimated $107K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #657 holding.
  • Eurizon Capital SGR SpA first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.